

## EPV1738

**Clinical efficacy and tolerability of Esketamine: a case series**

C. Passani<sup>1\*</sup>, N. Ragone<sup>1</sup>, C.M. Congedo<sup>1</sup>, B. Barbini<sup>2</sup>, R. Zanardi<sup>2</sup>, M.C. Cavallini<sup>2</sup> and C. Colombo<sup>3</sup>

<sup>1</sup>Università Vita Salute San Raffaele Hospital, Psychiatry, Mood Disorders Unit San Raffaele Turro, Milan, Italy; <sup>2</sup>IRCCS San Raffaele Scientific Institute, Psychiatry - Mood Disorders, Milano, Italy and

<sup>3</sup>Università Vita-Salute San Raffaele, Psychiatry, Milano, Italy

\*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2294

**Introduction:** Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD). The intranasal spray system appears to be more manageable than intravenous ketamine infusion. It contains ketamine's S- isomer which is four-fold more potent for the NMDA receptor.

**Objectives:** The aim of this case series is to describe our clinical experience in the use of Esketamine.

**Methods:** 6 TRD patients (3 men; 3 women) were recruited in San Raffaele Turro Hospital from March 2021. All patients (2 bipolar and 4 unipolar) were diagnosed with a Major Depressive Episode according to DSM-5 criteria, resistant to at least two antidepressants. Initially, Esketamine was administered twice weekly for one month; afterward, it was administered once weekly for a month; finally, it was administered once weekly or every two weeks for a month. Clinical scales (HAM-D, YMRS, SSI, HAM-A, MADRS, CADSS) were administered to assess symptoms and side effects before and after each administration on a weekly basis.

**Results:** Three patients out of six showed an improvement in depressive symptoms: two patients had remission (final HAM-D score < 8); one patient had a clinical response (final HAM-D score < 50 % respect baseline value). Three patients withdrew the treatment: two for perceived inefficacy, after 16 and 19 administrations, one for personal reasons.

**Conclusions:** The use of Esketamine in our TRD patients showed good effectiveness and tolerability but randomized controlled clinical trials are needed to confirm our findings.

**Disclosure:** No significant relationships.

**Keywords:** Depression; esketamine; treatment resistant depression

## EPV1737

**Caring for carers: A virtual psychosocial supervision intervention to improve the quality and sustainability of mental health and psychosocial support in humanitarian contexts**

R. Wells<sup>1\*</sup>, C. Acartuk<sup>2</sup>, F. Alameari<sup>2</sup>, M. Alokoud<sup>3</sup>, A. Beetar<sup>3</sup>, H. Eldardery<sup>4</sup>, M. Elshazly<sup>5</sup>, O. Faruk<sup>6</sup>, M.R. Ginem<sup>3</sup>, D. Hadzi-Pavlovic<sup>1</sup>, Z. Ilkkurşun<sup>2</sup>, S. Jahan<sup>6</sup>, R. Joshi<sup>1</sup>, L. Klein<sup>1</sup>, L. Kurdi<sup>3</sup>, G. Kurt<sup>2</sup>, C. Mastrogianni<sup>1</sup>, M. Mozumder<sup>6</sup>, S. Lekkeh<sup>3</sup>, S. Némorin<sup>7</sup>, K. Nicholson Perry<sup>8</sup>, M. Orabi<sup>9</sup>, J. Qasim<sup>10</sup>, Z. Steel<sup>1</sup>, M. Tavakol<sup>2</sup>, H. Ullah<sup>11</sup>, E. Uygun<sup>12</sup>, S. Wong<sup>1</sup>, L. (Fischer) Yan<sup>13</sup>, R. Said Youssef<sup>3</sup>, A. Zarate<sup>14</sup> and S. Rosenbaum<sup>1</sup>

<sup>1</sup>UNSW Sydney, Faculty Of Medicine, Sydney, Australia; <sup>2</sup>Koç University, Department Of Psychology, Istanbul, Turkey; <sup>3</sup>Hope Revival Organization, Hope Revival Organization, Gaziantep, Turkey;

<sup>4</sup>Istanbul Şehir University, Department Of Psychology, Istanbul, Turkey; <sup>5</sup>Independent consultant, N/a, Cairo, Egypt; <sup>6</sup>University of Dhaka, Department Of Clinical Psychology, Dhaka, Bangladesh; <sup>7</sup>NSW

Service For The Treatment And Rehabilitation Of Torture And Trauma Survivors (STARTTS), Nsw Service For The Treatment And Rehabilitation Of Torture And Trauma Survivors (startts), Carramar, Australia; <sup>8</sup>Australian College of Applied Psychology (ACAP), Discipline Of Psychological Science, Sydney, Australia; <sup>9</sup>Hope Revival Organization, Hope Revival Organization, Northwest Syria, Syria; <sup>10</sup>Isik University, Department Of Psychology, Istanbul, Turkey; <sup>11</sup>Independent consultant, N/a, Cox's Bazar, Bangladesh; <sup>12</sup>Bilgi University, Trauma And Disaster Mental Health, Istanbul, Turkey; <sup>13</sup>John Hopkins University, Department Of Mental Health, Baltimore, United States of America and <sup>14</sup>University of Denver, Graduate School Of Social Work & Josef Korbel School For International Studies, Denver, United States of America

\*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2295

**Introduction:** Mental health and psychosocial support (MHPSS) staff in humanitarian settings have limited access to clinical supervision and are at high risk of experiencing burnout. We previously piloted an online, peer-supervision program for MHPSS professionals working with displaced Rohingya (Bangladesh) and Syrian (Turkey and Northwest Syria) communities. Pilot evaluations demonstrated that online, peer-supervision is feasible, low-cost, and acceptable to MHPSS practitioners in humanitarian settings.

**Objectives:** This project will determine the impact of online supervision on i) the wellbeing and burnout levels of local MHPSS practitioners, and ii) practitioner technical skills to improve beneficiary perceived service satisfaction, acceptability, and appropriateness.

**Methods:** MHPSS practitioners in two contexts (Bangladesh and Turkey/Northwest Syria) will participate in 90-minute group-based online supervision, fortnightly for six months. Sessions will be run on zoom and will be co-facilitated by MHPSS practitioners and in-country research assistants. A quasi-experimental multiple-baseline design will enable a quantitative comparison of practitioner and beneficiary outcomes between control periods (12-months) and the intervention. Outcomes to be assessed include the Kessler-6, Harvard Trauma Questionnaire and Copenhagen Burnout Inventory and Client Satisfaction Questionnaire-8.

**Results:** A total of 80 MHPSS practitioners will complete 24 monthly online assessments from May 2022. Concurrently, 1920 people receiving MHPSS services will be randomly selected for post-session interviews (24 per practitioner).

**Conclusions:** This study will determine the impact of an online, peer-supervision program for MHPSS practitioners in humanitarian settings. Results from the baseline assessments, pilot evaluation, and theory of change model will be presented.

**Disclosure:** No significant relationships.

**Keywords:** humanitarian; MHPSS; supervision; online

## EPV1738

**Quality of life in patients with chronic hand eczema**

M. Bouhamed<sup>1\*</sup>, R. Sallemi<sup>1</sup>, K. Sallemi<sup>2</sup>, I. Feki<sup>1</sup> and J. Masmoudi<sup>1</sup>

<sup>1</sup>Hospital university of HEDI CHAKER, Psychiatry A Department, Sfax, Tunisia and <sup>2</sup>hedi chaker hospital, Dermatology, sfax, Tunisia

\*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2296

**Introduction:** Chronic hand eczema (CHE), inflammatory dermatitis, can lead to physical and psychosocial disability altering the quality of life of these patients.